Stock Price & Analysis

Based on the provided data and current market conditions, here's a concise analysis for PFE:

Technical Analysis The stock is currently trading at $26.31, showing signs of stabilization after a significant decline. RSI at 48.02 indicates neutral momentum, while the 20-day SMA at $26.53 suggests slight bearish pressure in the near term.

Fundamental Analysis Pfizer is currently trading at attractive valuations, with a forward P/E of approximately 9.1x based on 2025 earnings estimates. The company offers a substantial dividend yield of 6.5%, which appears sustainable with a payout ratio of 67% based on 2025 earnings guidance.

Recent Developments & Outlook

• Management projects earnings growth between 10-18% for 2025, with analysts estimating 14% annual growth over the next 3-5 years.
• The company is focusing on oncology growth following the Seagen acquisition ($43 billion) to offset declining COVID-19 product revenues.
• Specialty care products showed 11% YoY growth and oncology sales increased 25% through nine months of 2024.

Analyst Ratings Recent analyst actions show mixed sentiment:

• UBS: Hold, PT $29 (Jan 8, 2025)
• Truist Securities: Strong Buy, PT $32 (Dec 18, 2024)
• Guggenheim: Strong Buy, PT $33 (Dec 11, 2024)
• B of A Securities: Hold, PT $29 (Dec 10, 2024)

Conclusion SELL. Despite attractive valuations and a high dividend yield, the stock faces near-term headwinds from patent expirations and declining COVID-19 revenues. While the company's strategic shift towards oncology shows promise, it may take time for these initiatives to fully offset revenue losses. The current technical indicators suggest continued weakness, making it advisable to wait for clearer signs of reversal before establishing new positions.

Based on the provided data and market analysis, here is the price prediction for PFE stock in 2025:

PFE stock is expected to reach $31-32 by end of 2025, representing a ~20% upside from current levels of $26.30, driven by strong oncology growth and strategic acquisitions. The company's management is guiding 10-18% earnings growth for 2025, with analysts estimating 14% annual growth over the next 3-5 years.

The key catalyst will be Pfizer's focus on oncology expansion through the $43 billion Seagen acquisition, which is already showing results with 25% year-over-year growth in oncology sales. Additionally, the company's specialty care products grew 11% through first nine months of 2024.

The stock is currently trading at an attractive valuation of just 10x forward earnings, well below industry averages, while offering a sustainable 6.3% dividend yield. The combination of earnings growth and dividend yield could potentially deliver 20% annualized returns even without multiple expansion.

The S1 support level for PFE Stock is $25.98 ,The R1 resistant level for PFE Stock is $26.9.

As of the end of day on 2025-01-24, the price of PFE Stock was $26.08.

The target price for PFE Stock according to analyst rating is 31.47, with the highest price target at 45.00 and the lowest at 25.00. Analysts have a Moderate Buy rating on PFE Stock overall.

The market cap of PFE is $147.9B.

Based on the provided data and current market conditions, I'll analyze whether PFE is overvalued in 5 concise sentences:

PFE is currently trading at a forward P/E of 8.6x and EV/EBITDA of 8.62x in Q3 2024, which is significantly below its historical averages and industry peers, suggesting the stock is undervalued from a pure metrics perspective. The company's recent operational growth excluding COVID sales has been improving with rising margins, as evidenced by the 31% YoY growth in oncology division and strong performance in vaccines like Prevnar 20 and ABRYSVO. Despite facing patent expirations for some key drugs, Pfizer has a robust pipeline with multiple late-stage assets, particularly in oncology and obesity treatments, supported by over $75 billion in R&D investment since 2018. The company maintains strong FCF generation with $8.23 billion over TTM and recently increased its dividend by 2.4%, demonstrating financial stability despite current challenges. With management guiding FY2024 revenue of $61-64 billion (up from previous $59.5-62.5 billion) and adjusted EPS of $2.75-2.95 (up from $2.45-2.68), coupled with its extensive drug pipeline and current valuation metrics, PFE appears to be undervalued at current levels.

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Based on the available data and market analysis, here's a prediction for Pfizer (PFE) stock price in 2030:

Pfizer's stock is projected to reach approximately $45-50 per share by 2030, driven by its strong oncology growth strategy and the successful integration of Seagen acquisition. The company's strategic pivot to oncology and specialty care products, showing 25% year-over-year growth in oncology sales through 2024, supports this bullish outlook. Management's projected earnings growth of 10-18% for 2025 and analysts' estimates of 14% annual growth over the next 3-5 years provide a solid foundation for this long-term price target.

PFE has a total of 88000 employees.